MedeliX
Start asking

Rabeprazole

Pariet, Rabeprazol · ATC code A02BC04

Also known as: Rabeprazol, Aciphex · Brand names: Pariet, Rabeprazol Puren, Rabeprazol Tad, Patril, Peptyra, Prabex, Rabelis, Rabenol, Rabiza, Rabober, Raneks, Razogen, Ulsazol

Key facts
Active substance
Rabeprazole
ATC code
A02BC04
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-10-29

Key facts

Rabeprazole is a proton pump inhibitor (PPI). Per the US prescribing information, it is used for GERD, duodenal ulcers, Helicobacter pylori eradication and hypersecretory conditions.

What it is used for

  • Healing and maintenance of healing of erosive or ulcerative GERD in adults
  • Symptomatic GERD in adults and adolescents 12 years of age and older
  • Healing of duodenal ulcers
  • Helicobacter pylori eradication (with amoxicillin and clarithromycin) to reduce the risk of duodenal ulcer recurrence
  • Pathological hypersecretory conditions, including Zollinger-Ellison syndrome

Dosing

  • Erosive GERD: 20 mg once daily for 4 to 8 weeks; maintenance 20 mg once daily
  • Symptomatic GERD: 20 mg once daily for up to 4 weeks (adolescents up to 8 weeks)
  • Duodenal ulcer: 20 mg once daily after the morning meal for up to 4 weeks
  • H. pylori eradication: rabeprazole 20 mg, amoxicillin 1000 mg and clarithromycin 500 mg, all twice daily with meals for 7 days
  • Zollinger-Ellison syndrome: starting dose 60 mg once daily, then adjust
  • Swallow tablets whole; do not chew, crush or split; not recommended for children 1 year to less than 12 years

Contraindications

  • Known hypersensitivity to rabeprazole, substituted benzimidazoles or any component
  • Concomitant rilpivirine-containing products

Important warnings

  • Symptomatic response does not preclude gastric malignancy
  • Warfarin: increased INR and prothrombin time with possible bleeding
  • Acute tubulointerstitial nephritis; Clostridium difficile-associated diarrhea
  • Bone fracture with high-dose and long-term therapy; severe cutaneous reactions; lupus erythematosus
  • Long-term use: vitamin B-12 deficiency, hypomagnesemia, fundic gland polyps

Side effects

  • Pain (3%), pharyngitis (3%), flatulence (3%), infection (2%), constipation (2%)
  • Rare serious reactions: tubulointerstitial nephritis, C. difficile diarrhea, bone fracture, hypomagnesemia

Interactions

  • Antiretrovirals (e.g. rilpivirine, atazanavir, nelfinavir): decreased exposure
  • Warfarin: monitor INR and prothrombin time
  • Methotrexate (mainly high dose): raised levels and toxicity possible
  • Digoxin and tacrolimus: increased exposure, monitor levels; mycophenolate mofetil: reduced exposure

Pregnancy and breastfeeding

  • No human data; no adverse developmental effects in animal studies

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Austria

  • ParietJanssen-Cilag Pharma Gmbh · 1 register entry
  • Rabeprazol1a Pharma Gmbh, Teva B.V, Sandoz Gmbh, Adoh B.V., Krka, D.D., Novo Mesto · 6 register entries

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Germany

  • ParietEisai Gmbh · 1 register entry
  • Rabeprazol PurenPuren Pharma Gmbh & Co. Kg · 1 register entry
  • Rabeprazol TadTad Pharma Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Turkey

  • ParietJOHNSON AND JOHNSON SIHHİ MAL. SAN. VE TİC. LTD. ŞTİ. · 1 register entry
  • PatrilDEVA HOLDİNG A.Ş. · 2 register entries
  • PeptyraLİLYUM İLAÇ VE KİMYA SAN. TİC. A.Ş., LİLYUM İLAÇ VE KİMYA SAN. TİC. LTD. ŞTİ. · 2 register entries
  • PrabexSANDOZ İLAÇ SAN. VE TİC. A.Ş. · 4 register entries
  • RabelisCELTİS İLAÇ SAN. VE TİC. A.Ş., VİTALİS İLAÇ SAN. TİC. A.Ş. · 2 register entries
  • RabenolNEUTEC İLAÇ SAN. TİC. A.Ş · 1 register entry
  • RabizaİLKO İLAÇ SAN.VE TİC. A.Ş. · 2 register entries
  • RaboberBERKO İLAÇ VE KİMYA SAN. A.Ş. · 1 register entry
  • RaneksBİLİM İLAÇ SAN. VE TİC. A.Ş. · 3 register entries
  • RazogenGENVEON İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
  • UlsazolGEKEM İLAÇ SAN. VE TİC. LTD. ŞTİ. · 2 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

USA

  • AciphexWaylis Therapeutics LLC · 1 register entry

Source: U.S. FDA – Drug labels (openFDA/DailyMed), as of 2026-10-29

Brand names in 26 more European countries
Belgium
Pariet
Bulgaria
Ацилесол, Зулбекс, Рабиоксин
Croatia
Ares, Zulbex
Cyprus
Pariet, Rabeprazole Krka
Czechia
Rapoxol, Zulbex
Denmark
Pariet, Rabeprazol Medical Valley, Ralic
Estonia
Rabeprazole Actavis, Rabeprazole Doc Generici, Zulbex
Finland
Pariet, Rabeprazol Krka
France
Pariet, Rabeprazole Almus, Rabeprazole Arrow Generiques, Rabeprazole Bgr, Rabeprazole Biogaran, Rabeprazole Cristers, Rabeprazole Evolugen, Rabeprazole Sandoz, Rabeprazole Teva, Rabeprazole Viatris, Rabeprazole Zentiva, Rabeprazole Zydus, Rabéprazole Krka
Greece
Aircodos, Berlex, Pariet, Raberen
Hungary
Acilesol, Gelbra, Pariet, Rabeman, Rabeprazol, Ralic
Iceland
Pariet, Rabeprazol Actavis, Rabeprazol Krka, Rabeprazol Medical Valley
Ireland
Pariet, Rabeprazole Krka, Razole
Italy
Akirab, Pariet, Rabeprazolo Alter, Rabeprazolo Aurobindo Italia, Rabeprazolo Doc Generici, Rabeprazolo Krka, Rabeprazolo Sandoz, Rabeprazolo Tecnigen, Rabeprazolo Zentiva, Rabex, Starab
Latvia
Rabeprazole Adoh, Zulbex
Lithuania
Rabeprazole Actavis, Yzilan, Zulbex
Luxembourg
Pariet
Malta
Pariet
Netherlands
Beryx, Pariet, Praber, Rabeprazole Sodium Aurobindo, Rabeprazolnatrium Focus, Rabeprazolnatrium Krka, Rabeprazolnatrium Nevik, Rabeprazolnatrium Sandoz, Rabeprazolnatrium Teva, Rabeprazolnatrium Viatris
Poland
Zulbex
Portugal
Pariet, Rabeprazol Aurovitas, Rabeprazol Azevedos, Rabeprazol Basi, Rabeprazol Ciclum, Rabeprazol Farmalider, Rabeprazol Gap, Rabeprazol Generis, Rabeprazol Krka, Rabeprazol Mylan, Rabeprazol Sandoz, Rabeprazol Tolife, Rabeprazol Zentiva, Stom
Romania
Relitaz, Zulbex
Slovakia
Zulbex
Slovenia
Rabeprazol Lek, Zulbex
Spain
Pariet, Rabeprazol Almus, Rabeprazol Alter, Rabeprazol Aurovitas Spain, Rabeprazol Cinfa, Rabeprazol Combix, Rabeprazol Kern Pharma, Rabeprazol Krka, Rabeprazol Liconsa, Rabeprazol Normon, Rabeprazol Qualigen, Rabeprazol Sandoz, Rabeprazol Stada, Rabeprazol Sun, Rabeprazol Tarbis, Rabeprazol Tecnigen, Rabeprazol Teva-Ratio, Rabeprazol Viatris
Sweden
Pariet

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. Aciphex (Waylis Therapeutics LLC) – Prescribing Information, 2026-01-27. DailyMed (NLM), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1eb38279-0237-4967-be7a-c53a826c1138
  2. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  5. U.S. FDA – Drug labels (openFDA/DailyMed), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.